Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an arrangement to sell the remainder of its holding in the ordinary shares of Noxopharm Limited via a single block trade. Kazia expects the transaction to yield proceeds of approximately $2.1m, bringing the total gross proceeds from sale of our holding to approximately $2.4m.
For more information, download the attached PDF.
Download this document
